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Protocol for a randomized controlled trial
evaluating the effect of physical activity on
delaying the progression of white matter changes
on MRI in older adults with memory complaints
and mild cognitive impairment: The AIBL Active
trial
Elizabeth V Cyarto1, Nicola T Lautenschlager2,3, Patricia M Desmond4, David Ames1,2, Cassandra Szoeke1,5,
Olivier Salvado6, Matthew J Sharman7, Kathryn A Ellis1,2,8, Pramit M Phal4, Colin L Masters8,9, Christopher C Rowe10,
Ralph N Martins11 and Kay L Cox12*

Abstract
Background: Older adults free of dementia but with subjective memory complaints (SMC) or mild cognitive
impairment (MCI) are considered at increased risk of cognitive decline. Vascular risk factors (VRF), including
hypertension, heart disease, smoking, hypercholesterolemia and lack of physical activity (PA) have been identified as
modifiable risk factors contributing to cognitive decline, and white matter hyperintensities (WMH) are associated
with VRF, SMC and cognitive impairment. Findings from a growing number of clinical trials with older adults are
providing strong evidence for the benefits of physical activity for maintaining cognitive function, but few studies
are investigating these benefits in high-risk populations. The aim of AIBL Active is to determine whether a
24-month physical activity program can delay the progression of white matter changes on magnetic resonance
imaging (MRI).
Methods/design: This single-blind randomized controlled trial (RCT) is offered to 156 participants, aged 60 and
older, in the Melbourne arm of the Australian Imaging Biomarkers and Lifestyle Flagship Study of Aging (AIBL).
Participants must have SMC with or without MCI and at least one VRF. The PA intervention is a modification of the
intervention previously trialed in older adults with SMC and MCI (Fitness for the Ageing Brain Study). It comprises
24 months of moderate, home-based PA (150 minutes per week) and a behavioral intervention package. The
primary outcome measure will be change in WMH after 24 months on MRI. Cognition, quality of life, functional
fitness, level of physical activity, plasma biomarkers for cerebrovascular disease and amyloid positron emission
tomography (PET) imaging comprise secondary measures.
Discussion: Currently, there is no effective pharmacological treatment available to delay cognitive decline and
dementia in older adults at risk. Should our findings show that physical activity can slow down the progression of
WMH, this RCT would provide an important proof of concept. Since imbedded in AIBL this RCT will also be able to
investigate the interaction between vascular and Alzheimer's disease pathologies.
Trial Registration: Australia New Zealand Clinical Trials Registry ACTRN12611000612910
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Background
The proportion of the global population aged over 60
years is expected to increase from 11% in 2009 to 22%
by 2050 [1]. With increased longevity comes a greater
risk of developing age-related diseases, including cognitive impairment and dementia. In 2010, the estimated
number of people with dementia worldwide was 35.6
million with a projected increase to 115.4 million people
by 2050 [2].
Older adults at risk of cognitive decline are those free
of dementia but with subjective memory complaints
(SMC) and mild cognitive impairment (MCI). SMC is
defined as complaining about a deterioration of cognitive function without showing objective impairment
on cognitive testing [3] and MCI additionally requires
objective impairment on cognitive testing [4]. In the
United States, approximately 22% of the population aged
71 years and older have cognitive impairment not reaching the dementia threshold [5].
White matter hyperintensities (WMH) on structural
brain scans have been associated with cognitive impairment [6] and SMC in older adults [7] and have also been
identified as a risk factor for Alzheimer’s disease (AD) in
healthy older adults and MCI [8]. Further, WMH appear
to be more common and extensive in individuals with
vascular risk factors (VRF, eg hypertension, dyslipidemia,
obesity, diabetes, smoking) and cerebrovascular disease
(CVD) [9]. It has been hypothesized that CVD contributes to the increased risk for AD by damaging subcortical and cortical networks [10]. Brain white matter
damage may be indicated by the appearance of WMH
on T2-weighted images using magnetic resonance imaging (MRI) [8,11]. Thus, if the progression of white
matter changes could be reduced via altering modifiable
risk factors it might contribute to the prevention or
delay of cognitive decline.
It is well established that physical activity (PA) is essential for maintaining physical abilities and independence in old age [12]. For optimal health benefits, older
adults need at least 30 minutes of moderate-intensity
aerobic activity on five days each week [13]. Aerobic activities are recommended to improve cardiovascular outcomes and modify VRF such as obesity [14], lipid
profiles [15], blood pressure [16], glucose and insulin
metabolism [17]. More recently, observational studies
have demonstrated that PA is associated with a lower
risk of cognitive decline and dementia [18,19]. Barnes
and Yaffe [20] examined seven modifiable risk factors
for AD and projected the effect of risk factor reduction
on AD prevalence. They reviewed systematic reviews
and meta-analyses and used relative risk estimates and
prevalence data to calculate population attributable
risk (PAR), which is the percentage of cases of AD attributable to each factor. Physical inactivity potentially
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contributed to 13% of all cases of AD worldwide (almost
4.3 million), which is the third largest proportion of AD
cases after low education and smoking [20]. Further,
Barnes and Yaffe [20] estimated that reducing inactivity
by 10-25% could prevent between 380,000 to one million
cases of AD globally.
To date, a few randomized controlled trials (RCT), literature reviews and meta-analyses have shown that PA
has a positive effect on cognitive function for older adults
with healthy cognition, SMC, MCI and dementia [21-26].
To our knowledge only one other PA study is currently
underway that aims to reduce VRF in people at risk of dementia. Liu-Ambrose and colleagues [27] are conducting a
RCT of six months of moderate-intensity aerobic exercise
(walking) with 70 older adults with sub-cortical ischaemic
vascular cognitive impairment. They will measure cognitive function, executive function, activities of daily living,
physical function and blood biomarkers associated with
metabolic syndrome and inflammation. However, no study
has examined the brain white matter changes with PA.
Findings from animal research have generated several
hypotheses to explain the cognition-enhancing effects of
PA. These include neurogenesis [28,29], increased cerebral
blood flow [30], reduced neuroinflammation [31], reduced
brain beta-amyloid burden [32] and elevated levels of
brain-derived neurotrophic factor (BDNF, [33]). To test
these hypotheses, biological outcomes are starting to be
measured in clinical studies involving PA. However, there
have been mixed findings. For example, healthy older
adults who undertook one year of moderate-intensity aerobic activity (three days per week) experienced a 2% increase in hippocampal volume as measured by MRI [34].
This increase was associated with an increase in serum
BDNF and improved spatial memory. Baker and colleagues [22] measured fasting plasma levels of several ADrelated biomarkers (including BDNF and beta-amyloids 40
and 42) in participants with MCI before and after six
months of high-intensity aerobic exercise. Cognitive function improved, but, in contrast with Erickson et al. [34],
the researchers reported a gender difference in plasma
BDNF level. Compared with the control group, there was
a trend towards increased circulating BDNF concentrations in men but reduced levels in women [22].
The main purpose and novel aspect of the present
study is to conduct a methodologically rigorous RCT to
determine whether PA can delay the progression of
white matter changes, as measured by MRI, in community dwelling older adults with SMC and MCI who have
at least one VRF. Secondary objectives are to investigate
the effects of PA on cognition, well-being, physical function, plasma biomarker level for CVD and brain fibrillar
beta-amyloid load measured with beta-amyloid positron
emission tomography (PET) imaging. This paper
describes the design of the AIBL Active study.
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Methods/design

Participants

Study design

Community-dwelling older adults will be recruited in
Melbourne, Australia. Participants are individuals with
SMC or MCI with at least one VRF and who are also participants in the Australian Imaging, Biomarkers and Lifestyle

AIBL Active is a single blind RCT (Figure 1). The CONSORT statement has been used as a framework for development of the methodology for this project.

Figure 1 Study design.
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(AIBL) flagship study [35]. AIBL is a multi-disciplinary
prospective longitudinal study of ageing which follows
1112 older volunteers who live in Melbourne and Perth.
The aim of this study is to identify the predictive value of
biomarkers, cognitive variables and lifestyle factors for future progression to AD. AIBL participants belong to four
diagnostic categories - normal cognition, SMC, MCI and
Alzheimer’s disease. The AIBL study is ongoing, but to
date 61% of MCI and 40% of SMC from both sites showed
clinical progression on the Mini-Mental State Examination
(MMSE) at 18 months follow-up. Of the 325 Melbournian
participants with SMC and MCI, 214 (66%) have at least
one VRF [35].
Participants will be eligible for enrolment in AIBL Active
if they satisfy the following criteria: (i) aged 60 years or
over at last birthday, (ii) diagnosis of SMC or MCI, (iii)
community dwelling, (iv) presence of at least one VRF factor (such as obesity, hypertension, heart disease, type II
diabetes, smoking, hypercholesterolemia and doing less
than 150 min/week of moderate PA), (v) understands written and spoken English. Exclusion criteria include: (i) baseline Standardized Mini-Mental State Examination score
(SMMSE) < 24 [36] or diagnosis of dementia, (ii) unable to
have MRI scans, (iii) limited mobility (e.g. unable to walk
or require a walking aid for balance), (vi) show evidence of
pervasive depression, (v) current history of alcohol dependence, (vi) unstable or life-threatening medical condition, (vii) medical condition that contra-indicates PA, (viii)
severe visual or hearing impairment, (ix) unable to attend
the follow-up visits, or (x) participating in another RCT.
This study is funded by the National Health and Medical Research Council of Australia. Ethics approval has
been obtained from the Melbourne Health Human Research Ethics Committee and the project complies with
the Declaration of Helsinki.
Recruitment and screening

Potential participants will be identified for inclusion and
sent a letter of invitation by a member of the AIBL team.
Each participant will be asked to contact the AIBL Active
team by telephone and arrange a convenient time for a research assistant to check his/her eligibility (according to
the study inclusion and exclusion criteria) using a screening protocol.
The 15-item Geriatric Depression Scale (GDS – 15)
[37] is included as part of the phone screening to establish the presence of clinically relevant symptoms of depression, excluding potential participants with a score of
6 and higher. Participants will be asked to sign and return a release of medical information form to allow the
study team to access their medical records and their
physicians (and specialists if applicable) will be asked to
consent to their patients’ involvement in the study. Medical records will be reviewed by a member of the
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research team who is an experienced Geriatrician to
confirm the participants’ suitability for inclusion. Written informed consent will be obtained from participants
prior to commencing the study.
Assessments

Participants will be assessed at baseline and after six
months, 12 months and 24 months (see Table 1 for an
overview). There will be four components to the baseline
and 24-month assessments comprising 1) cognitive measures; 2) physical function measures/physical activity assessment; 3) MRI; and 4) a fasting blood sample. From
the 80 ml sample, lipid concentrations (total cholesterol,
LDL-C, HDL-C, triglycerides), fasting insulin, glucose,
homocysteine and hs-CRP will be measured. In addition,
blood samples will be analyzed for the following biomarkers: IL-6, TNF-α, sICAM-1, sVCAM-1, sP-selectin, sEselectin. At baseline only, participants will have a betaamyloid PET scan. Participants will undergo only the
first two components at their six- and 12-month visits
(see Table 1 for the measures administered at each time
point).
With the exception of the SMMSE (because it is administered at the start of the visit to determine eligibility),
the cognitive assessment will be administered by a
neuropsychology research assistant who will remain
blind to group allocation. The SMMSE and physical
assessments will be conducted by a physical activity research assistant (PA RA). The SMMSE [36] is a modified
version of the traditional Mini-Mental State Examination
(MMSE) [38], which benefits from greater objectivity
through more specific scoring examples as well as
alternatives for repeated testing of the registration and
delayed recall items. A score of less than 24 on the
SMMSE excludes participants from AIBL Active. The
PA RA will also collect demographic and health information via participant interview.
Measures administered by the neuropsychologist

The following 12 assessments comprise the cognitive
battery. The Alzheimer’s disease Assessment Scale –
Cognitive section (ADAS-cog) [39] consists of an 11item battery of short neuropsychological tests and is
widely used to monitor the progression of cognitive deficits in clinical trials. Here we will use a version incorporating a delayed verbal recall task.
The Cambridge Contextual Reading Test (CCRT) [40]
includes the words of the National Adult Reading Test
(NART), embedding them within appropriate semantic
and syntactic contexts to provide a reliable measure of
pre-morbid intelligence. The CCRT is only administered
at baseline.
The Clinical Dementia Rating Scale (CDR) [41] is a
widely used clinical staging instrument for dementia,
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Table 1 Outline of the assessments and timelines of AIBL active
Telephone
Screen

Baseline

6 months

12 months

24 months

Standardized Mini-Mental State Examination

X

X

X

X

Cambridge Contextual Reading Test

X

Alzheimer’s disease Assessment Scale – Cognitive section

X

X

X

X

Clinical Dementia Rating Scale

X

X

X

X

Measure
Geriatric Depression Scale – 15 item

X

Consortium to Establish a Registry for Alzheimer’s Disease battery

X

Wisconsin Card Sorting Test (WCST-64)

X

X
X

X

N-Back Task

X

X

X

Trails A & B/Trail Making Test

X

X

X

Behavior Rating Inventory of Executive Function – Adult Version

X

X

X

Short Form-36 version 2 (SF-36v2)

X

X

X

X

Hospital Anxiety and Depression

X

X

Memory Complaint Questionnaire

X

Everyday Competence Questionnaire

X

Resting blood pressure

X

Height, weight, body composition, girths
Step test

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

Sit-to-stand test

X

X

X

X

Grip strength

X

X

X

X

Timed Up and Go test

X

X

X

X

Six-minute walk

X

X

X

X

Community Healthy Activities Model Program for Seniors (CHAMPS) questionnaire

X

X

X

X

Stages of Change Instrument

X

X

X

X

Satisfaction with Life Scale

X

X

X

X

Self-Efficacy Questionnaire

X

X

X

X

X

X

X

Content and program evaluation
Blood sample collection

X

X

MRI scan

X

X

PET scan

X

The X indicates at which point of the trial the respective assessments will take place.

useful for globally staging the level of impairment: 0 = No
impairment, 0.5, 1, 2, and 3 indicate very mild, mild, moderate and severe dementia, based on a semi-structured
interview.
The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) neuropsychological assessment
battery [42] is sensitive to early cognitive impairment.
The individual tests are: verbal fluency, Boston Naming
Test, MMSE, word list and constructional praxis. It will
be used to help determine whether participants have a
classification of MCI at baseline.
The Wisconsin Card Sorting Test (WCST-64) [43] is a
well- established measure of executive function and is
more specifically a neuropsychological test of setshifting, i.e. the ability to display flexibility in the face of

changing schedules of reinforcement. The WCST-64
comprises two decks of 64 cards. The computerized version will be used, which allows more timely administration and instant scoring, while reducing the potential for
administration and scoring errors.
The n-Back Task [44] is a measure of working memory.
In the most typical variant of the n-Back Task, the participant is required to monitor a series of stimuli and to
respond whenever a stimulus is presented that is the same
as the one presented n trials previously, where n is a prespecified integer, usually 1, 2, or 3. The task requires
on-line monitoring, updating, and manipulation of
remembered information and is therefore assumed to
place great demands on a number of key processes within
working memory.
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The Trails A & B/Trail Making Test (TMT) [45] provides information on visual search, scanning, speed of
processing, mental flexibility, and executive functions.
The TMT consists of two parts. TMT-A requires an individual to draw lines sequentially connecting 25
encircled numbers on a sheet of paper. Similar tasks are
required for TMT-B except the person must alternate
between numbers and letters.
The Behavior Rating Inventory of Executive Function –
Adult Version (BRIEF-A) [46] is a standardized measure
that captures views of an adult's executive functions or
self-regulation in his or her everyday environment. The
BRIEF-A is composed of 75 self-report items within nine
non-overlapping theoretically and empirically derived clinical scales that measure various aspects of executive
functioning.
The Short Form-36v2 [47] is a 36-item questionnaire
that assesses the health and well-being of the participant
across eight dimensions; physical functioning, social
functioning, role limitations due to physical problems,
role limitations due to emotional problems, mental
health, energy/vitality, pain, and general health perception. Health change over the past year is also assessed.
The Hospital Anxiety and Depression Scale (HADS)
[48] is a 14-item self-rating instrument designed to assess the presence and severity of anxiety and depressive
symptoms in medical patients. The scale consists of separate seven-item subscales for depression and anxiety
and can be used within hospital out-patient, primarycare, and community settings for all age groups.
The Memory Complaint Questionnaire (MAC-Q) [49]
is a six-item scale of self-reported memory decline in
which participants compare current memory ability with
past performance for given situations. Scores range from
7 to 35 with higher scores reflecting perceived cognitive
decline.
The Everyday Competence Questionnaire (ECQ) [50]
comprises 17 items that evaluate a person’s ability to
perform activities essential to independent living, such
as housekeeping, leisure activities and mobility.
Measures administered by the PA RA

The test battery for the physical assessment will include
resting blood pressure, height, weight, body composition,
waist and hip girths, step test for dynamic balance [51],
Timed Up and Go (TUG) Test for mobility [52], five
timed chair stands [53] for lower limb strength and maximum voluntary hand grip strength. All of these measures are described in the published protocol for the
Fitness for the Ageing Brain Study II (FABS II) [54]. For
cardiovascular endurance, participants will perform the
6-minute walk test [55]. Participants will be instructed
to walk as fast as possible around a 20-metre measured
course as many times as they can in six minutes. The
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maximum distance walked, heart rate and rate of perceived exertion [56] will be recorded.
Several questionnaires used in FABS II [54] will also
be administered in AIBL Active, including the Community Healthy Activities Model Program for Seniors
(CHAMPS) physical activity questionnaire [57], Stages
of Change Instrument (SCI) [58], Self-Efficacy Questionnaire (SEQ) [59], and Satisfaction with Life Scale [60].
Participants will be provided with a pedometer (DigiWalker SW-200, Yamax Inc., Tokyo, Japan) and asked to
wear it for five weekdays and the weekend, following the
baseline and other visits, to objectively measure their
weekly PA. Participants will be shown how to wear and
use the pedometer and how to complete the diary. Participants will be instructed to maintain their usual activity
pattern during the monitoring period. Pedometers are
recognised as objective and valid measures of PA in
older adult populations [61].
Neuroimaging

MRI scan
All scanning will be performed on a Siemens (Erlangen,
Germany) 3T Tim Trio Scanner using a 12-channel phased
array coil. High resolution data sets will be acquired to
allow accurate evaluation of brain atrophy and white matter
disease. Seven MRI sequences will be acquired: 1) Sagittal
T1 weighted Magnetization Prepared Rapid Gradient Echo
(MPRAGE) MRI; isotropic 1mm voxel (TR = 1900ms, TE
= 2.13ms, flip angle = 9°, TI = 900ms); 2) Sagittal 3D Fluid
Attenuated Inversion Recovery (FLAIR); isotropic 1mm
voxel (TR = 5000ms, TE = 355ms, flip angle = 120°, TI =
1800ms); 3) Axial T2 Turbo Spin Echo; 36 slices, 3mm
thickness, 0mm gap, in plane resolution of 0.9x0.9 mm (TR
= 3000ms, TE = 98ms); 4) Resting state imaging: 7min
35sec acquisition; Blood Oxygenation Level Dependent
(BOLD) contrast, single-shot, T2*-weighted, gradient-echo
planar imaging (EPI) sequence; 34-slice acquisition (TR =
2500 ms, TE = 30ms, flip angle = 90°, voxel size = 3.0 mm;
5) Diffusion Tensor Imaging: FOV 240, 55 slices, 2.5/0
thickness, TR = 8700ms, TE = 122ms, Resolution 96 x 96,
B values 0 and 1000, 30 directions and bandwidth 1408; 6)
Arterial Spin Labelling: FOV 192, 14 slices, 6/1.5 thickness,
TR = 2500ms, Te = 11ms, Resolution 64 x 64, TI (1) =
700ms, TI (2) = 1800ms, Bandwidth 2232 and 101 measurements; and 7) Susceptibility weighted imaging (SWI); 1 x 40
slice axial volume, 4mm thickness, 0.8mm gap, in plane
resolution of 0.5 x 0.5 mm (TR = 40ms, TE = 30ms, flip
angle = 15°).

Visual assessment of white matter disease progression
and medial temporal lobe atrophy
White matter hyperintensities (WMH) at baseline will
be rated using the Scheltens scale (range, 0 to 84 points)
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[62]. Visual assessment of progressive white matter disease
will be performed using the modified Rotterdam Progression Scale [63]. This score ranges from 0 to 9, scoring stable
(0) or increase (1) in 9 regions. Intra and inter rater reliability for these methods will be assessed and have previously
been shown to be high [64]. Medial Temporal lobe Atrophy
(MTA) has been linked to both progressive white matter
disease [65] and cognitive decline [66] in MCI participants.
Visual assessment of the medial temporal lobes will be
performed on coronal T1 images from the volume set
according to the 5 point (0–4) Scheltens scale from the
average score of the left and right sides [67].

Volumetric MRI analysis
Volumetric analysis of the white matter lesions will be
performed at a laboratory equipped with FSL (http://www.
fmrib.ox.ac.uk/fsl) and Analyze (http://www.analyzedirect.
com) software packages. A semi-automated threshold
region of interest (ROI) based approach to white matter
lesions will be used. All ROIs selected will be reviewed by a
neuro-radiologist to confirm accurate identification of
lesions and accurate identification of contours of lesions.
The volume of the lesions will be summed to give a total
lesion volume or total WMH. This will be standardized to
the whole brain volume to control for individual differences
in brain size. A fully automated measure of white matter
lesions will be undertaken using published automated
image processing algorithms [68] and compared with the
results of the semi-automated supervised technique. Similarly, volumetric analysis of the medial temporal lobe will
be performed manually and in an automated fashion. The
manual segmentation will be performed by identifying the
contours of the hippocampus on coronal T1 weighted
images, employing well defined anatomical landmarks [69].
This will be compared to an automated technique. Hippocampal volumes will be standardized to the whole brain
volume to control for individual differences in brain size.

PET scan
The PET ligand F-18 Florbetapir (previously known as F-18
AV-45) will be used to image in vivo amyloid, based on the
presence of amyloid plaques in the brains of AD patients.
This compound was conceived of, synthesised, and clinically developed at the University of Pennsylvania and Avid
Radiopharmaceuticals Pty Ltd (Philadelphia). This drug has
completed Phase III clinical trials and been submitted to
the Food and Drug Administration for marketing approval
as a diagnostic test for the detection of amyloid plaques.
No adverse effects have been found during the clinical
development of this compound.

PET image acquisition
Participant preparation consists of intravenous (IV)
catheterization and immobilization of the head with a
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Velcro strap. The scan will require an IV bolus administration over 30 sec of 370 MBq (less than 5 micrograms)
of high specific activity F-18 Florbetapir. Fifty minutes
post injection of the compound, a 15 minute scan will
be acquired using a Phillips Allegro PET camera.
Co-registration of each participant’s MRI with the PET
images will be performed and an MRI ROI template
transferred to the co-registered PET. Standardized uptake value ratios (SUVR) will be generated by normalizing to the cerebellar cortex. Neocortical beta-amyloid
burden will be expressed as the average SUVR of the
area-weighted mean of frontal, superior parietal, lateral
temporal, lateral occipital, and anterior and posterior
cingulate regions.
Randomization and blinding

Randomization will be undertaken in blocks of six participants (three in each of the treatment arms). The blocks
were generated in STATA 10 (StataCorp, TX, USA). An
investigator not directly involved in the recruitment or
assessment of participants will perform allocation to
study groups. Due to logistic difficulties, participants will
not be blind to the intervention and sham PA will not
be used. However, the “clinical staff” involved in the collection of endpoints will not be aware of group allocation (single blind). Blinding will be supported by the
performance of cognitive and physical assessments at
different locations and explicit instructions to participants and research staff not to discuss issues related to
PA during the assessments.
Intervention

The intervention period will be 24 months divided into
4 stages; Stage 1: 0–6 months; Stage 2: 6–12 months;
Stage 3: 12–18 months; Stage 4: 18–24 months, with review at the end of each stage (Figure 1). The intervention will comprise three components: the PA program,
the behavioral intervention package, and telephone monitoring. Participants randomized to the intervention will
return for a PA workshop within two to four weeks of
their baseline visit. During this 60-minute session, the
PA RA will give participants their program manual and
explain the participants’ PA program and the behavioral
intervention package.
Physical activity program

Participants will be advised to perform at least 150 min/
week of moderate PA as per the PA recommendations
for older people [70]. Where walking is a suitable and
acceptable option to the participant, this will be a primary PA recommendation. Examples will be given on
how this can be achieved. The program will be individualized based on the CHAMPS and SCI data, and the
person’s interests. Activities prescribed will take into
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account health problems or other limitations, and participants will be instructed to start slowly and progress
gradually taking eight weeks to reach the target amount
and intensity. Participants will be encouraged to achieve
the 150 min/week by completing 3 x 50 minutes sessions
(most PA classes range between 45–60 minutes). In previous studies with middle-aged and older women using
this format, we have demonstrated good retention, adherence and improvements in cardiovascular fitness and
blood pressure [71]. Participants who already perform
150min/week of PA will be encouraged to increase their
PA by adding one 50-minute session. Some participants
might choose to complete activities in community centers. This home-based PA program was successful in
maintaining retention, increasing PA and improving cognition in participants with MCI and those with subjective memory complaints [24]. Modifications have been
made to the PA program and other components of the
intervention to enhance motivation and to maintain PA
over the 24-month intervention.
In order to maintain standardization of the physical
activity programs one CI will monitor the programs prescribed by the PA RA. The PA program will include
instructions on how to read the program, complete the
activities, record their sessions, and exercise safely. Participants will be given a simple diary to record their PA.
The diaries, once completed, will be mailed back to the
PA RA at the end of each month.
Adherence during the intervention will be calculated
from the number of sessions completed and recorded on
the exercise diaries. This will be expressed as a percentage of the number of sessions completed relative to the
number of sessions prescribed.

Behavioral intervention

Participants will receive the same educational material and
recommendations for a healthy lifestyle as the control
group. In addition they will receive a manual containing
the PA program and the behavioral intervention (BI). The
intervention program will be based on the Stages of
Change model modified for PA [58], which has been
shown to be effective in increasing and maintaining PA in
middle-aged and older women [71]. This approach is based
on the development of self-efficacy (the belief that one has
the ability to perform a task) to promote change [72]. It
will also draw on another key component of social cognitive theory and behavior change self-regulation; the personal regulation of goal directed behavior or performance
[72,73]. The BI program will aim to develop self-efficacy by
promoting practical strategies to enhance both physical
skills and self-regulation skills. We will use our previously
successful strategies [71] with the addition of greater emphasis on identifying and setting goals, self-monitoring,
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giving relevant feedback, review of progress and identifying
action steps to enhance self-regulation skills.
Strategies to increase adherence to the program will be
discussed during the workshop and worksheets will be
included in a manual. During the 24-month trial, the PA
RA will mail newsletters at regular intervals to participants, which contain additional motivational information.
This will also be reinforced during the 18 telephone calls
made at regular intervals. Participants will be contacted by
telephone for a standardized and structured 15-minute
interview to monitor and give feedback on their progress
and encourage their continuing adherence. In addition
pedometers will be given to the participants for the duration of the study and midway through each 6-month
period they will be asked to record their daily steps for 4
weeks while trying to reach a personalized target.
Pedometer-based interventions have been shown to be an
effective way to help maintain PA in older adults [74]. Participants will also be given a PA report after their followup assessments. Giving feedback about progress and increasing participants’ perceived benefits of being more
physically active has been shown to increase program adherence [75].
Content and program evaluation

At the end of each follow-up visit, the intervention group
participants will be asked to complete a brief interview
questionnaire on the content and processes of the program including how easy the program was to understand
and follow, and any barriers that were encountered.
Control group

Control group (usual care) participants will receive educational material and recommendations for a healthy
lifestyle (other than PA). Participants will be contacted
by telephone at the same frequency as the intervention
group to ensure that the control and intervention group
have similar treatment except for the actual intervention.
Conversation for this group will be limited to their general health and will not include discussion about PA. At
the end of each follow-up visit, control group participants will be asked to complete a brief interview questionnaire related to their involvement in the study. At
the conclusion of the study, these participants will be
offered the opportunity to attend an educational session
on PA.
Statistical methods

Participants who drop out during the trial will be invited
to return for the follow-up assessments. We will use imputation by chain equations (ICE) to estimate possible
missing outcomes in an intention-to-treat analysis (primary analysis). A complete-case analysis will also be
conducted, which includes participants with valid data at
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all time points. We will use multilevel regression models
to take into account repeated measures and intraindividual variability (mixed models). These models will
be adjusted for confounding should the randomization
produce unbalanced groups.
The volumetric change in WMH white matter load at
24 months and the modified WMH change score will be
assessed using an independent 2-sample t-test or Mann–
Whitney U test, depending on whether the data satisfies
assumptions of normality. The modified WMH change
score may also be collapsed into a smaller number of
categories and assessed using a chi-square test. General
linear models will then be used to estimate treatment
effects after correcting for initial WMH severity, age, depression, MTA, cognition and VRF. The predictive contribution of these confounding variables will also be
investigated. Model assumptions of normality and constant variance will be checked and data will be transformed if required. A multiple imputation method will
be applied to replace missing observation values during
the follow-up for key analysis variables if necessary. The
change in secondary outcomes, cognition, fitness, depression, quality of life and functional levels, between
baseline and 24 months and between groups will be analyzed. General linear models will be fitted for each outcome separately and known confounding variables will
also be included in this analysis. Frequency counts and
chi square analyses will be used to determine the distribution of subjects for retention in the study and demographic data. Changes in PA, fitness, blood pressure,
body weight, body composition and socio-psychological
variables will be analyzed across the entire follow-up
period, using repeated measures mixed model analysis.
Amyloid status is another important explanatory variable
in the progression of WMH. This will be incorporated
into the general linear model described in the analysis of
the primary outcome. The interaction effect between
amyloid status and treatment will also be included in the
model to assess whether amyloid status influences patient response to treatment.

lesion (WML) change score (range 0 to 9) [63]. After
two years participants in the vascular care group had
less progression of WMH compared to the standard care
group (1.4 versus 2.3, p = 0.03) with a significant linear
trend (p=0.009). We hypothesize that in our participants
the effect of the PA program on WMH would be similar
to that of vascular care intervention. Based on the WML
change, with a medium effect size of 0.5, 80% statistical
power and a two-sided alpha error level of 0.05, we
therefore would need 65 participants per group. Allowing for 15% loss to follow-up we will need 76.5 participants per group. We will recruit 78 participants per
group for a total of 156 participants.

Sample size and power calculation

Competing interests
The authors declare that they have no competing interests.

The primary outcome of interest in this study is change
of WMH on follow-up MRI after two years. To our
knowledge there is no study having investigated the effect of PA on progression of WMH in older adults with
SMC and MCI. However in a recent RCT, Richard et al.
[76] compared WMH progression in 123 participants
with AD who received either vascular care or standard
care over a two-year period. Vascular care was defined
as treating vascular risk factors as good as possible.
Scans were analyzed and WMH at baseline were rated
using visual semi-quantitative rating scales. Progression
of WMH was measured using the modified while matter

Discussion
With the global incidence of dementia projected to rise
dramatically over the next several decades, developing
effective strategies to reduce the risk of cognitive decline
or slow its progression is critical. Physical activity has
been successfully used to modify VRF [77] and it has
more recently been proven to benefit cognition in individuals with MCI [22,24,78]. Since white matter changes
are considered a risk factor for cognitive decline, testing
the efficacy of PA as a strategy to delay the progression
of white matter changes in those at risk is timely.
This trial builds on the strengths of the Fitness for the
Ageing Brain Study (FABS) [24] and, if successful, will
provide proof of concept. In contrast to FABS and other
RCTs on PA and cognition, AIBL Active investigates the
effect of PA on biomarkers and progression of WMH in
older adults with SMC and MCI and VRF. Building on the
AIBL study, we will also be able to examine the associations between trial outcomes and brain beta-amyloid load
measured with PET. This can help to identify the clinical
populations that may benefit the most from such an intervention. The findings have the potential to inform practitioners and provide the impetus for translation into
community programs. This trial may represent an affordable and safe method to delay the onset of cognitive decline and cognitive impairment in older adults at risk.
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